CorMedix Announces SPA Agreement With FDA For Phase 3 Trial in the Prevention of Contrast-Induced Acute Kidney Injury Study With CRMD001

CorMedix Inc. CRMD announced it has received a Special Protocol – Agreement letter from the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 trial for the Company's oral formulation of CRMD001 in the prevention of Contrast-Induced Acute Kidney Injury. This SPA takes into consideration a modification to the dosing regimen contained in the previously submitted protocol.